We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Copart
CPRT
$27.4B
| $21.6M | 0.03% |
550,563
-33,992
| -6% | -$1.41M |
|
402
NNN REIT
NNN
$9.16B
| $21.5M | 0.03% |
542,371
+36,461
| +7% | +$1.49M |
|
403
Q2 Holdings
QTWO
$3.7B
| $21.4M | 0.03% |
297,014
-16,692
| -5% | -$1.15M |
|
|
TXNM
404
TXNM Energy Inc
TXNM
$6.42B
| $21.4M | 0.03% |
363,564
-31,005
| -8% | -$1.79M |
|
405
Weyerhaeuser
WY
$16.9B
| $21.4M | 0.03% |
902,284
-27,586
| -3% | -$638K |
|
406
MakeMyTrip
MMYT
$5.37B
| $21.4M | 0.03% |
260,177
+45,100
| +21% | +$3.7M |
|
407
Amdocs
DOX
$5.87B
| $21.2M | 0.03% |
263,287
+30,723
| +13% | +$2.47M |
|
408
WSFS Financial
WSFS
$4.1B
| $21.2M | 0.03% |
383,212
-18,517
| -5% | -$1.01M |
|
409
NeoGenomics
NEO
$2.04B
| $21.2M | 0.03% |
1,798,939
+1,006,676
| +127% | +$10.9M |
|
410
Estee Lauder
EL
$30.7B
| $21.1M | 0.03% |
201,255
+23,717
| +13% | +$2.3M |
|
411
Burford Capital
BUR
$922M
| $21M | 0.03% |
2,357,279
+497,780
| +27% | +$4.87M |
|
412
Vericel Corp
VCEL
$2.43B
| $21M | 0.03% |
583,884
+41,018
| +8% | +$1.51M |
|
413
Teledyne Technologies
TDY
$30.1B
| $21M | 0.03% |
41,065
-259
| -0.6% | -$136K |
|
414
Fair Isaac
FICO
$26.4B
| $20.9M | 0.03% |
12,356
-580
| -4% | -$998K |
|
415
CoStar Group
CSGP
$12B
| $20.8M | 0.03% |
310,072
-1,555
| -0.5% | -$110K |
|
416
Atmus Filtration Technologies
ATMU
$4.22B
| $20.8M | 0.03% |
400,699
-23,522
| -6% | -$1.14M |
|
417
Ducommun
DCO
$2.77B
| $20.8M | 0.03% |
218,433
+14,721
| +7% | +$1.37M |
|
418
Texas Roadhouse
TXRH
$13.7B
| $20.7M | 0.03% |
124,587
-14,291
| -10% | -$2.42M |
|
419
Mid-America Apartment Communities
MAA
$15.5B
| $20.7M | 0.03% |
148,672
-4,694
| -3% | -$625K |
|
420
Flex
FLEX
$41B
| $20.6M | 0.03% |
340,685
+5,498
| +2% | +$340K |
|
421
Enpro
NPO
$6.61B
| $20.5M | 0.03% |
95,771
-26,146
| -21% | -$5.78M |
|
422
ON Semiconductor
ON
$32.6B
| $20.5M | 0.03% |
378,552
+11,458
| +3% | +$588K |
|
423
Leidos
LDOS
$14.1B
| $20.5M | 0.03% |
113,452
-10,162
| -8% | -$1.93M |
|
424
Kilroy Realty
KRC
$4.6B
| $20.4M | 0.03% |
546,882
+25,548
| +5% | +$1.04M |
|
425
Edgewise Therapeutics
EWTX
$4.42B
| $20.4M | 0.03% |
821,940
+202,062
| +33% | +$4.06M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.